0 results

    Portfolio News

    Sofinnova Capital

    Myricx Bio Announces Board Changes

    Related Deal lead

    Maina Bhaman

    Related Strategy

    Capital

    Related Company

    Myricx Bio

    London, UK, 09 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the following board changes.

    Dr Rachael Brake has stepped down as an independent Non-Executive Director.

    Co-founder Professor Ed Tate has stepped down as Director but remains a Board Observer and closely involved with the company as a N-Myristoyltransferase (NMT) key opinion leader and Scientific Advisor to the company.

    Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth have joined the Myricx’ Board as Investor Directors. Other board directors are Chris Martin, Independent Chair, Robin Carr, CEO, and Maina Bhaman from Sofinnova and Jonathan Tobin from Brandon Capital as Investor Directors.

    Chris Martin, Chairman and Non-Executive Director of Myricx Bio said, “On behalf of the board I would like to take this opportunity to acknowledge and thank Rachael for everything she has done to help Myricx reach this point in the company’s evolution over the past two years. Rachael brought her +20 years’ experience in advancing therapeutic programs across various mechanisms of action and modalities in oncology and her deep experience of drug development to Myricx. Both in and outside board meetings Rachael has worked energetically to enable the company to sharpen its science strategy, and to understand how to effectively validate and position its novel NMT inhibitor platform.”

    Myricx recently announced the closing of its series A financing raising £90m ($114m).

    -Ends-

    Notes to Editors:

    About Myricx Bio – www.myricxbio.com

    Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-Myristoyltransferases (NMT) for the treatment of cancer.

    NMT is an enzyme that adds a specific lipid modification to a number of protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

    Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Abingworth, Brandon Capital Partners, British Patient Capital Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, Sofinnova Partners.

    Follow us on LinkedIn

    For further information please contact

    At the Company
    Dr Robin Carr, CEO, Myricx Bio
    info@myricxbio.com

    Media Enquiries
    Sue Charles, Charles Consultants
    sue@charles-consultants.com
    +44 (0)7986 72658

    Join our mailing list

    Keep up to date with our latest news.

    Required
    Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.